About Suzhou Kintor
- Time of issue:2019-04-14 00:00:00
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Over the years, the company has developed a diverse product pipeline with androgen receptors (AR) related diseases at the core. Our products cover multiple global high incidence cancers and other disease areas that have huge unmet medical needs, including COVID-19, prostate cancer, breast cancer, liver cancer, alopecia and acne, etc. Kintor has developed a visionary product pipeline including small molecule innovative drugs, biologics and the combination therapies. The diversified product pipeline includes 6 products that are undergoing clinical research, including androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR inhibitors ，Hedgehog/SMO inhibitors and AR - Degrader. The company also has diverse ongoing preclinical programs, such as PD-L1/TGF-β dual-targeting antibody and c - Myc inhibitors etc. The company is granted more than 60 patents worldwide, and many of the Group's projects have been listed as the National Special Project for "Significant Novel Drugs Development" during the 12th and 13th Five-Year Plan period.
The company's main product, Proxalutamide, is undergoing clinical trials both in China and the United States. There are two phase III clinical trials ongoing in China for second-line therapy and first-line therapy of mCRPC patients and one phase II clinical trial in the United States also for mCRPC patients. Pyrilutamide, a treatment for androgenetic alopecia, is undergoing the phase II clinical trial in China. ALK-1 monoclonal antibody is undergoing phase II clinical trials in combination with PD-1 (Nivolumab) for the treatment of liver cancer in Taiwan. Meanwhile, the preparation for the company’s commercialization of products has been carried out. In August 2020, its R&D center and industrialization base located in the Suzhou Industrial Park were officially capitalized, with a coverage of approximately 20,000 square meters, and a sum of RMB200 million investment volume.The site will be fully functional in 2020. The base is designed and constructed in full compliance with the international GMP standard and used all the available state of art technologies to meet the production needs of the company's pharmaceutical products. After years of efforts, Kintor Pharmaceuticals has built a comprehensive,innovative pharmaceutical platform that integrates research, development, production, and commercialization.
Two founders not only have rich experience in the research and development of novel drugs, but also have experience in management of start-up pharmaceutical companies. Under their leadership, the company has attracted a group of outstanding domestic and foreign experts, with experience at leading multinational pharmaceutical companies and rich experience that covers the spectrum of drug development, such as biology, medicinal chemistry, pharmacodynamics, pharmaceutical research, immunology research, clinical research, production, and commercialization.
Scan the QR code to read on your phone